Document Detail

Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers.
MedLine Citation:
PMID:  22853865     Owner:  NLM     Status:  Publisher    
Objective: Fesoterodine is a pro-drug of the active metabolite 5-hydroxymethyl tolterodine (5-HMT), a muscarinic receptor antagonist. This study aimed to evaluate the safety profile and pharmacokinetic characteristics of multiple oral doses of sustained-release fesoterodine (fesoterodine SR) in healthy Korean males. Methods: A randomized, double-blind, placebo-controlled, multiple-dose study with two oral doses (4 mg and 8 mg) was conducted in healthy Korean male participants. The study drug was administered once daily for 5 days. The plasma concentration of 5-HMT was measured up to 72 hours after the last drug administration. The CYP2D6 genotype was analyzed using polymerase chain reaction (PCR) methods to assess the effect of genetic polymorphisms on the pharmacokinetic parameters. Results: 20 participants completed the study. The mean (SD) areas under the plasma concentration-time curves during the dosing interval (AUCτ) of the 4 mg and 8 mg dose groups were 26.1 (8.0) and 64.2 (30.5) μg∙h/ml and the mean peak concentrations (Cmax) were 2.6 (0.7) and 6.0 (2.0) μg/ml, respectively, at steady-state. The mean AUCτ and Cmax of 5-HMT increased in approximately the same proportion as the dose increased. Fesoterodine SR was well tolerated without any serious adverse events or abnormal clinical laboratory findings. Conclusion: Systemic 5-HMT exposure showed dose-proportional characteristics in the 4 mg to 8 mg dose range in healthy Korean males. Thus, 4 mg or 8 mg doses of fesoterodine SR taken once-daily were tolerable in healthy Korean males.
Dongseong Shin; Kwang-Hee Shin; Seunghwan Lee; Kyoung Soo Lim; Joo-Youn Cho; In-Jin Jang; Sang-Goo Shin; Kyung-Sang Yu
Related Documents :
6094795 - Anti-shock actions of a new converting enzyme inhibitor, enalaprilic acid, in hemorrhag...
6763895 - Effect of the catecholestrogen 2-hydroxyestradiol on the renin-angiotensin system in th...
22409295 - Chemoimmunotherapy with ofatumumab in combination with chop in previously untreated fol...
22550315 - Effects of belimumab, a b lymphocyte stimulator-specific inhibitor, on disease activity...
23207645 - In vivo dosimetry with semiconductors in medium dose rate (mdr) brachytherapy for cervi...
23296435 - Oral sildenafil as a rescue therapy in presumed acute pulmonary hypertensive crisis.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-1
Journal Detail:
Title:  International journal of clinical pharmacology and therapeutics     Volume:  -     ISSN:  0946-1965     ISO Abbreviation:  Int J Clin Pharmacol Ther     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9423309     Medline TA:  Int J Clin Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Performance of commercial ELISA and agglutination test kits for the detection of anti-Toxoplasma gon...
Next Document:  Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report...